Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.
You may also be interested in...
To secure long-term growth, Hikma CEO Siggi Olafsson is seeking to add a fourth strategic pillar to its global generic Injectables, US non-injectable Generics and Middle East and North Africa Branded business segments.
Hikma has set out updated full-year forecasts in a trading update that indicates its 2019 generics sales will hit the “top end” of its $690m-$720m expectations.